Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) Patent Expiration, LOE Window & CMS Spending

Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen) by Mallinckrodt: Off-Patent Genericized (AB Competition), 0 AB generics, $462.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMallinckrodt
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$462.6M
2024 Medicare Part D Spend$387.0M
2024 Medicaid Spend$75.6M
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 26.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Mallinckrodt across sibling Meru public-data platforms.